Retatrutide

Development stage

Phase III (TRIUMPH program) active; BLA filing planned Q1 2027; not yet FDA approved as of mid-2026.

Legal and regulatory

Investigational New Drug; not FDA approved.

Side effects

GI symptoms (nausea, vomiting, diarrhea) common to incretin-class drugs; long-term safety still under study